MTA2

MTA2 is a core subunit of the NuRD (nucleosome remodeling and histone deacetylase) chromatin remodeling complex that recruits HDAC1/2 to gene promoters to repress transcription through histone deacetylation, thereby governing immune cell differentiation, genomic imprinting, epithelial-mesenchymal transition, and tissue lineage identity. Within the NuRD complex, MTA2 forms a stable sub-complex with RBBP7 in a 2:4 stoichiometry (PMID:28179136), directly binds MBD3 (PMID:12124384), and is recruited to specific genomic loci by transcription factors including AIOLOS/IKAROS, Snail, Twist, HIF-1α, and HNF4A/SATB2 to repress targets such as IL-4, E-cadherin, PTEN, and surrogate light chain genes (PMID:18353770, PMID:31291582, PMID:30814496, PMID:29708271, PMID:38678016). Beyond transcriptional repression, MTA2 interacts with the fork-protection factor Tipin to facilitate Polα loading at replication forks and associates with replication origins, linking it to DNA replication integrity (PMID:24830473, PMID:34280886). MTA2 protein stability is post-translationally regulated by p300-mediated acetylation at K152, ubiquitin-mediated degradation counteracted by UCHL3 and HMGB2, neutrophil elastase-mediated C-terminal cleavage, and cytoplasmic sequestration by lncRNA SNHG5 (PMID:24468085, PMID:38474064, PMID:41092376, PMID:30642362, PMID:27065326).

1. 2002 High

   Establishing MTA2 as a direct NuRD subunit resolved how MBD3 bridges methyl-CpG recognition to the deacetylase machinery: MBD3's MBD domain was necessary and sufficient for binding both HDAC1 and MTA2.

   Evidence Recombinant protein interaction assays with wild-type and mutant MBD3

   PMID:12124384

   Open questions at the time

   • Stoichiometry and architecture of the full NuRD complex not resolved
   • Whether MTA2 and MTA1 compete for the same MBD3 binding site was untested
2. 2008 High

   Demonstrating that Mta2 knockout caused lupus-like autoimmunity with T cell hyperactivation and elevated cytokines (IL-2, IL-4, IFN-γ) established MTA2/NuRD as a physiological transcriptional repressor of cytokine genes in T cells.

   Evidence Whole-body and T cell-specific conditional knockout mice, bone marrow transplantation, gene expression analysis

   PMID:18353770

   Open questions at the time

   • Genome-wide identification of direct MTA2 target genes in T cells was lacking
   • Whether MTA2 loss affects other immune lineages beyond T cells was not addressed
3. 2010 High

   Showing that MTA2 knockdown caused biallelic H19 expression and loss of differential methylation at imprinting control regions extended MTA2/NuRD function to epigenetic maintenance of genomic imprints during preimplantation development.

   Evidence RNAi in mouse preimplantation embryos, allele-specific expression, bisulfite sequencing

   PMID:20720167

   Open questions at the time

   • Whether MTA2 recruits DNMTs directly to imprinted loci was unresolved
   • Contribution of other NuRD subunits versus MTA2-specific function not distinguished
4. 2012 High

   ChIP demonstration that MTA2 recruits HDAC1 to the FSHR promoter in Sertoli cells, with MTA2 itself being FSH-inducible, revealed a negative feedback circuit desensitizing FSH signaling.

   Evidence siRNA knockdown, ChIP, gene expression analysis in Sertoli cell culture

   PMID:23086931

   Open questions at the time

   • In vivo validation in conditional testis-specific knockout was not performed
   • Whether this feedback is conserved across species was untested
5. 2014 Medium

   Identification of p300-mediated acetylation at MTA2 K152, whose mutation impaired cancer cell growth, established that MTA2 is itself a regulated substrate rather than solely a regulator of histone acetylation.

   Evidence Co-immunoprecipitation, mass spectrometry, site-directed mutagenesis, cell functional assays

   PMID:24468085

   Open questions at the time

   • How K152 acetylation affects NuRD complex assembly or chromatin binding was not tested
   • Deacetylase responsible for removing K152 acetylation was not identified
6. 2014 High

   Reconstitution in Xenopus egg extracts showed MTA2 interacts with the fork-protection factor Tipin and is required for Polα loading at replication forks, establishing a non-transcriptional role for MTA2/NuRD in DNA replication integrity.

   Evidence Xenopus egg extract replication assays, electron microscopy of replication intermediates, protein interaction studies

   PMID:24830473

   Open questions at the time

   • Whether MTA2's replication role is independent of its HDAC-recruitment function was unclear
   • Whether this mechanism operates at all genomic loci or preferentially at centromeres was not fully resolved
7. 2016 Medium

   Discovery that lncRNA SNHG5 sequesters MTA2 in the cytoplasm, preventing NuRD assembly and increasing histone/p53 acetylation, revealed a post-transcriptional layer of MTA2 regulation through RNA-mediated subcellular trapping.

   Evidence Co-immunoprecipitation, subcellular fractionation, acetylation assays in cancer cell lines

   PMID:27065326

   Open questions at the time

   • Direct RNA-protein binding (e.g., CLIP) was not demonstrated
   • Structural basis for SNHG5–MTA2 interaction unknown
8. 2017 High

   Structural characterization of the intact MTA2-RBBP7 sub-complex at 2:4 stoichiometry by negative-stain EM revealed an elongated architecture with hinge-like flexibility, establishing this heterohexamer as the initial assembly intermediate of NuRD.

   Evidence Recombinant expression/purification from HEK293F cells, negative stain EM, 3D reconstruction

   PMID:28179136

   Open questions at the time

   • High-resolution (cryo-EM or crystal) structure not obtained
   • How the MTA2-RBBP7 sub-complex docks with HDAC1/2 and CHD3/4 was not resolved
9. 2018 High

   Elucidation of a reciprocal positive-feedback loop — HIF-1α transcriptionally upregulates MTA2, and MTA2/HDAC1 deacetylates HIF-1α to stabilize it — connected MTA2 to hypoxia signaling and explained its role in E-cadherin repression and EMT under hypoxic conditions.

   Evidence ChIP, Co-IP, luciferase reporter assay, acetylation assays, xenograft models

   PMID:29708271

   Open questions at the time

   • Whether MTA2-HIF-1α feedback operates in non-cancer physiological contexts was not tested
   • Other substrates of MTA2/HDAC1-mediated deacetylation beyond HIF-1α were not catalogued
10. 2019 High

    Three studies collectively expanded MTA2's transcription factor partnerships and target gene repertoire: MTA2/NuRD is recruited by AIOLOS/IKAROS to repress surrogate light chain genes during B cell development, by Snail to repress PTEN and activate PI3K/AKT signaling, and MTA2 loss causes derepression via increased H3K27 acetylation.

    Evidence Co-IP, ChIP-seq, conditional B cell KO mice (AIOLOS/IKAROS study); ChIP-seq, luciferase assay, xenograft (PTEN study); mutagenesis and NE inhibitor treatment (cleavage study)

    PMID:30642362 PMID:30814496 PMID:31291582

    Open questions at the time

    • Whether AIOLOS versus IKAROS recruit distinct MTA2-containing NuRD sub-complexes was unresolved
    • Genome-wide overlap between MTA2 and Snail targets was not comprehensively mapped
11. 2021 Medium

    Multiple studies converged on MTA2 as a central EMT regulator: MTA2 interacts with EIF4E to upregulate Twist, with AIB1/SRC-3 to co-repress E-cadherin, and with CHD4 at bivalent chromatin domains guided by LINC00941 to maintain epidermal progenitor identity, while SNHG5 promotes MTA2 ubiquitin-mediated degradation to reverse EMT.

    Evidence Co-IP, ChIP, expression microarray, RNA pulldown, ubiquitination assay, interactome proteomics, organotypic tissue models, CUT&TAG

    PMID:33095847 PMID:33340431 PMID:33420368 PMID:34280886 PMID:38649186

    Open questions at the time

    • Identity of the E3 ubiquitin ligase targeting MTA2 for degradation was not established
    • Whether MTA2-EIF4E interaction is direct or bridged through NuRD components was unclear
    • Whether CUT&TAG-identified origin binding reflects direct DNA contact or indirect chromatin association was not distinguished
12. 2024 High

    Demonstration that MTA2 co-occupies chromatin with HNF4A and SATB2 at colonic enhancers, and that MTA2 loss causes HNF4A redistribution to small intestinal chromatin, established MTA2/NuRD as a guardian of tissue lineage identity in the gut.

    Evidence Proteomics, CRISPR-Cas9 screening, ChIP-seq, conditional KO mice, lipid uptake assays

    PMID:38678016

    Open questions at the time

    • Whether MTA2 directly binds HNF4A or requires SATB2 as an obligate bridge was not resolved
    • Whether MTA1 or MTA3 can compensate for MTA2 loss at colonic enhancers was untested
13. 2024 Medium

    Identification of circMTA2–UCHL3 interaction and HMGB2-mediated protection of MTA2 from ubiquitination revealed two independent mechanisms stabilizing MTA2 protein, with downstream effects on HIF-1α-dependent glycolysis and cardiac regeneration.

    Evidence Co-IP, ubiquitination assays, IP-MS, cardiomyocyte-specific KO/OE mouse models, exosome isolation

    PMID:38474064 PMID:41092376

    Open questions at the time

    • The E3 ligase mediating MTA2 ubiquitination remains unidentified
    • Whether UCHL3 and HMGB2 operate on the same or distinct ubiquitin chains on MTA2 was not tested
    • In vivo relevance of circMTA2-mediated stabilization beyond gastric cancer is unknown

• The identity of the E3 ubiquitin ligase(s) targeting MTA2 for proteasomal degradation, the high-resolution structure of MTA2 within the complete NuRD complex, and the rules determining which transcription factors recruit MTA2/NuRD versus MTA1/NuRD or MTA3/NuRD to specific genomic loci remain unknown.
• No E3 ligase identified for MTA2 ubiquitination
• No high-resolution cryo-EM structure of MTA2-containing NuRD
• Paralog-specific functions of MTA1 vs MTA2 vs MTA3 within NuRD not systematically resolved